DSM Announces Joint Collaboration Agreement with AdeTherapeutics to Develop Novel Scar Reduction Product for Spine Surgeries

November 29, 2011 10:00 AM Eastern Time
DSM Announces Joint Collaboration Agreement with AdeTherapeutics to Develop Novel Scar Reduction Product for Spine Surgeries

BERKELEY, Calif.--(BUSINESS WIRE)--DSM, a global leader in biomedical materials, today announced that it has signed a joint collaboration agreement with AdeTherapeutics to accelerate the company's scar reduction and pain management product development strategy in neurosurgery, specifically in spine surgery and craniotomy.

"This is another important step in building our presence in drug delivery and furthering DSM's ambitions in biomedical materials"

The primary objective of this collaboration is to combine the drug delivery expertise of DSM with the therapeutic and clinical development expertise of AdeTherapeutics to create the world's first product to address scar tissue formation (epidural fibrosis) after spinal surgery. The success of this project may be expanded to craniotomies.

Scar tissue formation has been linked to 20-36% of failed back surgery syndrome (FBSS) cases, which often cause patients debilitating pain. With over one million spine surgery procedures done in the US alone, FBSS represents a significant unmet need and burden to the healthcare system. With the aging population, spine surgery rates are expected to climb significantly.

Leading the project development will be Stanford and Cleveland Clinic-trained neurosurgeon Dr. Michael Kelly. "The clinical relevance is obvious, because we see too many patients back in the OR due to chronic pain, nerve root compression and other complications related to epidural fibrosis," says Dr. Kelly. "Furthermore, build up of scar tissue makes it challenging for us to perform repeat surgeries, and any improvement would be welcomed by neurosurgeons and their patients. Therefore, I am very excited to be a part of this project to develop materials and methods to help reduce this type of scarring and to work with a global leader such as DSM to bring this much needed product to the market."

"This is another important step in building our presence in drug delivery and furthering DSM's ambitions in biomedical materials," said Donato DiBiase, Business Director, Drug Delivery, DSM Biomedical. "Being active in both materials sciences and life sciences, DSM is in a unique position to create new, innovative products that address societal needs. This collaboration with AdeTherapeutics is a perfect example. AdeTherapeutics' novel approach to pain management and scar reduction combined with DSM's expertise in biomaterials and drug delivery is a fruitful collaboration. We are excited about the potential of this relationship."

"DSM offers extensive experience and resources, and has a leading position in the fast growing biomedical materials market," said Sanj Singh, Chief Executive Officer, AdeTherapeutics. "This, combined with AdeTherapeutics' team of esteemed surgeons and novel approach to wound healing, helps to meet our vision of becoming a worldwide leader in developing products that address complications related to surgery, such as post operative pain due to scar formation. We have the best minds around the table and this collaboration is an example of that."

DSM - Bright Science. Brighter Living.TM

Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about € 9 billion. The company is listed on NYSE Euronext. More information can be found at http://www.dsm.com.

About AdeTherapeutics, Inc.

AdeTherapeutics is a privately held, market-driven, clinical-stage product development company located in Canada. The company's vision is to become the worldwide leader in developing products that deal with complications related to surgery. The company's core competencies lie in its ability to translate clinical insight to the lab and then to the bedside. The team consists of PhD/MD surgeons, individuals with clinical trial expertise and regulatory experts. The company has C-level management and board and advisory board members who add significant value to patients and the health care system. The company has developed and patented a novel therapeutic approach for the prevention and reversal of adhesions or scar tissue, a worldwide problem that occurs in 93% of surgeries. AdeTherapeutics has expanded its novel approach to additional applications where adhesions and/or scarring are a significant problem including laminectomies (spinal surgeries), craniotomies, orthopaedics, ophthalmology, cosmetic plastic surgery and keloids (dermal).

Contacts

Kwittken & Company
Abhi Basu, 646-747-7174
[email protected]

 

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.